UB Paderborn / Katalog / Suche / in CDI

1 – 22 von 22

Sortiert nach

Pre- or post-treatment with the mitochondrial uncoupler 2,4-dinitrophenol attenuates striatal quinolinate lesions

Brain research, 2003-03, Vol.966 (2), p.312-316

2003

Volltextzugriff (PDF)

Effect of Recombinant Human Growth Hormone and Insulin-Like Growth Factor-1 Administration on IGF-1 and IGF-Binding Protein-3 Levels in Brain Injury

Pharmacotherapy, 1999-12, Vol.19 (12), p.1432-1436

1999

Volltextzugriff (PDF)

Systemically Administered IGF-I/Growth Hormone Increases IGF-I Concentration in the CSF of Patients with Traumatic Brain Injury Paper #708

Neurosurgery, 1996-09, Vol.39 (3), p.638

1996

Volltextzugriff (PDF)

Systemically Administered IGF-I/Growth Hormone Increases IGF-I Concentration in the CSF of Patients with Traumatic Brain Injury

Neurosurgery, 1996-09, Vol.39 (3), p.638-638

1996

Volltextzugriff (PDF)

Evaluation of the pharmacokinetics of pemigatinib in patients with impaired hepatic or renal function

British journal of clinical pharmacology, 2022-01, Vol.88 (1), p.237-247

2022

Volltextzugriff (PDF)

Achieving a physiological cortisol profile with once-daily dual-release hydrocortisone: a pharmacokinetic study

European journal of endocrinology, 2016-07, Vol.175 (1), p.85

2016

Volltextzugriff (PDF)

Physiologically‐based pharmacokinetic model‐based translation of OATP1B‐mediated drug–drug interactions from coproporphyrin I to probe drugs

Clinical and translational science, 2022-06, Vol.15 (6), p.1519-1531

2022

Volltextzugriff (PDF)

Evaluation of drug-drug interactions of pemigatinib in healthy participants

European journal of clinical pharmacology, 2021-12, Vol.77 (12), p.1887-1897

2021

Volltextzugriff (PDF)

An Open‐Label Study to Assess the Effect of Itraconazole and Rifampin on Parsaclisib Pharmacokinetics When Administered Orally in Healthy Participants

Journal of clinical pharmacology, 2020-11, Vol.60 (11), p.1519-1526

2020

Volltextzugriff (PDF)

Effect of Cyclosporin A and Impact of Dose Staggering on OATP1B1/1B3 Endogenous Substrates and Drug Probes for Assessing Clinical Drug Interactions

Clinical pharmacology and therapeutics, 2022-06, Vol.111 (6), p.1315-1323

2022

Volltextzugriff (PDF)

Correction to: Evaluation of drug‑drug interactions of pemigatinib in healthy participants

European journal of clinical pharmacology, 2021-12, Vol.77 (12), p.1899-1899

2021

Volltextzugriff (PDF)

Effect of Hepatic Impairment on the Pharmacokinetics of Itacitinib

Journal of clinical pharmacology, 2021-07, Vol.61 (7), p.954-960

2021

Volltextzugriff (PDF)

Abstract CT243: Clinical trial simulation to inform dose selection of zilurgisertib, an ALK2 inhibitor, in patients with anemia due to myelofibrosis (MF)

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (8_Supplement), p.CT243-CT243

2023

Volltextzugriff (PDF)

Phase I Safety and Pharmacokinetic Study of the PI3K/mTOR Inhibitor SAR245409 (XL765) in Combination with Erlotinib in Patients with Advanced Solid Tumors

Journal of thoracic oncology, 2014-03, Vol.9 (3), p.316-323

2014

Volltextzugriff (PDF)

Pharmacokinetics of Subcutaneous C1 Esterase Inhibitor (human) with Recombinant Human Hyaluronidase for the Prevention of Angioedema Attacks in Patients with Hereditary Angioedema

Journal of allergy and clinical immunology, 2015-02, Vol.135 (2), p.AB192-AB192

2015

Volltextzugriff (PDF)

Effect of the acute-phase response on the pharmacokinetics of chlorzoxazone and cytochrome P-450 2E1 in vitro activity in rats

Drug metabolism and disposition, 1999-09, Vol.27 (9), p.1074

1999

Volltextzugriff (PDF)

Subcutaneous administration of human C1 inhibitor with recombinant human hyaluronidase in patients with hereditary angioedema

Allergy and asthma proceedings, 2016-11, Vol.37 (6), p.489

2016

Volltextzugriff (PDF)

Tumor pharmacokinetics (PK) and pharmacodynamics (PD) of SAR245409 (XL765) and SAR245408 (XL147) administered as single agents to patients with recurrent glioblastoma (GBM): An Ivy Foundation early-phase clinical trials consortium study

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.2012-2012

2013

Volltextzugriff (PDF)

Abstract A134: Pharmacokinetics and metabolism of iniparib for the treatment of metastatic triple-negative breast cancer (TNBC)

Molecular cancer therapeutics, 2011-11, Vol.10 (11_Supplement), p.A134-A134

2011

Volltextzugriff (PDF)

Phase I Trial of SAR245408 (S08), a Pan-Phosphatidylinositol 3 Kinase (PI3K) Inhibitor, in Patients with Chronic Lymphocytic Leukemia (CLL) and Lymphoma

Blood, 2011-11, Vol.118 (21), p.2683-2683

2011

Volltextzugriff (PDF)

A Phase I Dose Expansion Cohort Study of the Safety, Pharmacokinetics and Pharmacodynamics of SAR245409 (S09), An Orally Administered PI3K/mTOR Inhibitor, in Patients with Lymphoma

Blood, 2011-11, Vol.118 (21), p.1608-1608

2011

Volltextzugriff (PDF)

The effect of brain injury and the acute -phase response on the pharmacokinetics and metabolism of endogenous and exogenous substrates

Rockich, Kevin Thomas

1999

Volltextzugriff (PDF)

1 – 22 von 22

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(21)
Mit Volltextzugriff
(16)

Publikationsform

Artikel
(21)
Dissertationen
(1)

Sprache

Englisch
(22)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Pre- or post-treatment with the mitochondrial uncoupler 2,4-dinitrophenol attenuates striatal quinolinate lesions

Effect of Recombinant Human Growth Hormone and Insulin-Like Growth Factor-1 Administration on IGF-1 and IGF-Binding Protein-3 Levels in Brain Injury

Systemically Administered IGF-I/Growth Hormone Increases IGF-I Concentration in the CSF of Patients with Traumatic Brain Injury Paper #708

Systemically Administered IGF-I/Growth Hormone Increases IGF-I Concentration in the CSF of Patients with Traumatic Brain Injury

Evaluation of the pharmacokinetics of pemigatinib in patients with impaired hepatic or renal function

Achieving a physiological cortisol profile with once-daily dual-release hydrocortisone: a pharmacokinetic study

Physiologically‐based pharmacokinetic model‐based translation of OATP1B‐mediated drug–drug interactions from coproporphyrin I to probe drugs

Evaluation of drug-drug interactions of pemigatinib in healthy participants

An Open‐Label Study to Assess the Effect of Itraconazole and Rifampin on Parsaclisib Pharmacokinetics When Administered Orally in Healthy Participants

Effect of Cyclosporin A and Impact of Dose Staggering on OATP1B1/1B3 Endogenous Substrates and Drug Probes for Assessing Clinical Drug Interactions

Correction to: Evaluation of drug‑drug interactions of pemigatinib in healthy participants

Effect of Hepatic Impairment on the Pharmacokinetics of Itacitinib

Abstract CT243: Clinical trial simulation to inform dose selection of zilurgisertib, an ALK2 inhibitor, in patients with anemia due to myelofibrosis (MF)

Phase I Safety and Pharmacokinetic Study of the PI3K/mTOR Inhibitor SAR245409 (XL765) in Combination with Erlotinib in Patients with Advanced Solid Tumors

Pharmacokinetics of Subcutaneous C1 Esterase Inhibitor (human) with Recombinant Human Hyaluronidase for the Prevention of Angioedema Attacks in Patients with Hereditary Angioedema

Effect of the acute-phase response on the pharmacokinetics of chlorzoxazone and cytochrome P-450 2E1 in vitro activity in rats

Subcutaneous administration of human C1 inhibitor with recombinant human hyaluronidase in patients with hereditary angioedema

Tumor pharmacokinetics (PK) and pharmacodynamics (PD) of SAR245409 (XL765) and SAR245408 (XL147) administered as single agents to patients with recurrent glioblastoma (GBM): An Ivy Foundation early-phase clinical trials consortium study

Abstract A134: Pharmacokinetics and metabolism of iniparib for the treatment of metastatic triple-negative breast cancer (TNBC)

Phase I Trial of SAR245408 (S08), a Pan-Phosphatidylinositol 3 Kinase (PI3K) Inhibitor, in Patients with Chronic Lymphocytic Leukemia (CLL) and Lymphoma

A Phase I Dose Expansion Cohort Study of the Safety, Pharmacokinetics and Pharmacodynamics of SAR245409 (S09), An Orally Administered PI3K/mTOR Inhibitor, in Patients with Lymphoma

The effect of brain injury and the acute -phase response on the pharmacokinetics and metabolism of endogenous and exogenous substrates

Suchergebnisse filtern